LOS ANGELES--(BUSINESS WIRE)--HemaCare Corporation (OTCBB: HEMA), a leader in cell and tissue collection, processing, and cell therapy solutions, has expanded its global capabilities through a strategic distribution agreement in Israel with Almog Diagnostic. This partnership ensures researchers in the Israeli life sciences community can access HemaCare’s human healthy and disease state hematopoietic cell products for their basic scientific and cell therapy research and development needs in a timely manner and with local regional support.
“HemaCare’s experience in operating FDA-registered, cGMP/cGTP compliant donor centers, expertise in cell isolation and processing, and access to a repository of highly profiled reliable and recallable donors make HemaCare a partner of choice to support the unique needs and requirements of the global scientific community”
HemaCare distribution agreements enable partners to actively provide support to customers. Researchers will be able to obtain human biological material collected from HemaCare’s FDA-registered donor collection centers, as well as fresh and frozen hematopoietic cell products derived from its cell isolation laboratory in California, while receiving customer service and technical support in their native language through specially trained representatives locally in their region. To ensure best in class service and support, HemaCare provides ongoing technical training and marketing support to its global partners. A complete list of HemaCare’s distribution partners can be found here.
“HemaCare’s experience in operating FDA-registered, cGMP/cGTP compliant donor centers, expertise in cell isolation and processing, and access to a repository of highly profiled reliable and recallable donors make HemaCare a partner of choice to support the unique needs and requirements of the global scientific community,” said Pete van der Wal, Chief Executive Officer for HemaCare.
About HemaCare
HemaCare specializes in the customization of human-derived biological products and services for customer’s research and cell therapy protocols. HemaCare’s network of FDA-registered, GMP/GTP-compliant collection centers ensures donor material is available for fresh shipment to customers, as well as for internal use within HemaCare’s isolation laboratory. In this laboratory, human biological material such as peripheral blood, bone marrow, and cord blood from donor and patient subjects is isolated into various primary cell types for distribution to customers in fresh and frozen formats. HemaCare’s extensive registry of well-characterized repeat donors provides consistent primary human cells and biological products for advanced biomedical research and cellular therapy process development.
For 39 years, HemaCare has provided human-derived primary blood cells and tissues for biomedical research, supported cell therapy clinical trials and commercialization with apheresis collections, and provided a wide range of consulting services. HemaCare directly supports benchtop immunology and oncology research, compound screening for drug discovery, and assay development and qualification, as well as enables customers to advance both autologous and allogeneic cellular therapies. For more information, please visit www.hemacare.com.
HemaCare:
Lou Juliano
(631) 521-9497
ljuliano@hemacare.com
